Atara Biotherapeutics, Inc. (ATRA)

Trade ATRA now with
4/5/2022 4:07:33 PM Atara Biotherapeutics Appoints Charlene Banard As Chief Technical Officer
2/18/2022 8:07:17 AM Atara Updates On ATA2271 Autologous CAR T Trial; MSK Voluntarily Pauses Enrollment Of New Patients
12/13/2021 8:14:45 PM Atara Biotherapeutics Announces Positive Results From Pivotal Phase 3 Trial Of Tab-cel
12/9/2021 8:08:34 AM Atara : Vitro Functional Studies Show Potent Antitumor Activity Of ATA2271 Following Repeat Antigen Stimulation
11/30/2021 8:45:33 AM EMA Validates Atara' MAA For Tabelecleucel For Treatment Of EBV+ PTLD
10/13/2021 7:35:15 AM Atara Presents Two-Year Data From Open Label Extension Of ATA188 For Progressive Multiple Sclerosis
10/4/2021 7:36:04 AM Atara Biotherapeutics And Pierre Fabre Enter Strategic Collaboration To Commercialize Tabelecleucel
9/29/2021 3:45:46 AM Atara Biotherapeutics To Present Phase 1 Study Update Of ATA188 In Progressive Multiple Sclerosis At ECTRIMS 2021
9/27/2021 8:38:37 AM EMA Grants Atara Accelerated Assessment Of Tab-cel For The Treatment Of Epstein-Barr Virus Positive
7/2/2021 4:12:14 PM Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
1/4/2021 8:46:53 AM Atara Provides Regulatory Update For Tab-Cel For Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
5/29/2019 6:58:07 AM Wedbush Reiterates Atara Biotherapeutics, Inc. (ATRA) At Outperform
4/1/2019 7:19:33 AM William Blair Reiterates Atara Biotherapeutics, Inc. (ATRA) At Outperform
4/2/2018 8:33:33 AM William Blair Reiterates Atara Biotherapeutics, Inc. (ATRA) At Outperform